Trial Profile
A Randomized Phase 1-2 Study of PLM60 in Patients With Peripheral T-Cell Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 21 Dec 2020
Price :
$35
*
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Conjupro Biotherapeutics
- 14 Oct 2020 Planned initiation date changed from 15 Jul 2019 to 1 Jan 2021.
- 14 Oct 2020 Status changed from suspended to withdrawn prior to enrolment.
- 06 Jun 2019 Planned End Date changed from 31 Jul 2022 to 1 Jan 2025.